Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Doxorubicin Stories

2014-04-17 16:26:55

LAGUNA HILLS, Calif., April 17, 2014 /PRNewswire/ -- NanoSmart(®) and NanoValent, private pharmaceutical companies developing novel cancer pharmaceuticals, have entered into a research collaboration agreement to explore the feasibility of jointly developing an ANA-conjugated liposomal doxorubicin nanoparticle for the treatment of ovarian cancer and other solid tumors. The joint project combines NanoValent's hybrid polymerized liposomal nanoparticle (HPLN), which can be loaded with...

2014-03-19 23:26:27

A new study indicates that an investigational drug for relapsed Non-Hodgkin’s Lymphoma called pixantrone (Pixuvri) is safer for the heart than the current front-line treatment. Raleigh, NC (PRWEB) March 19, 2014 Research published in Reproductive Toxicology and reported by the Non-Hodgkin’s Lymphoma Center suggests that there may be a better treatment option for people with relapsed or refractory (recurrent) aggressive Non-Hodgkin’s Lymphoma. Non-Hodgkin’s Lymphoma patients who...

2014-03-19 08:29:44

New Investment Will Fund the Company's Upcoming Phase 2 Clinical Trial in Sarcoma Patients BIRMINGHAM, Ala., March 19, 2014 /PRNewswire/ -- Gem Pharmaceuticals announced today that current Gem boardmembers/investors Diane Hendricks and Karl Leo have agreed to provide up to $4.5 million in new capital in order to fund the Company's upcoming Phase 2 clinical trial of GPX-150 in sarcoma patients. These funds will be invested over the course of the trial. Photo -...

2014-03-07 23:21:39

A new article in a top medical journal says appropriate use of a safer chemotherapy drug could open up more treatment options for Non-Hodgkin’s Lymphoma patients. Raleigh, NC (PRWEB) March 07, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on a new article published in Leukemia & Lymphoma journal suggesting that an alternative to a popular Non-Hodgkin’s Lymphoma drug can reduce the risk of heart problems and help more patients. This is especially good news for elderly...

2014-02-18 23:26:46

MarketResearchReports.Biz announces addition of new report “AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014” to its database. Visit: http://www.marketresearchreports.biz/analysis/187350. Albany, NY (PRWEB) February 18, 2014 Global Markets Directs, 'AIDS Related Kaposi's Sarcoma Pipeline Review, H1 2014', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for AIDS Related Kaposi's...

2014-02-04 08:34:07

QUÉBEC CITY, Feb. 4, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company's cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone ("LHRH") receptors. The article,...

2014-02-03 08:27:19

QUÉBEC CITY, Feb. 3, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11(th) International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014. The session will be held on Tuesday, February 11, 2014, in Hall A of the Wyndham Hotel in Salzburg. Presentations are scheduled as follows:...

2013-11-19 08:28:41

Findings Highlight Company's Growing Hematologic Area of Focus, Including Ibrutinib, Siltuximab and Daratumumab RARITAN, N.J., Nov. 19, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen compounds have been selected for presentation at the 55(th) American Society of Hematology (ASH) Annual Meeting in New Orleans, LA. Nine pieces of company-sponsored research will be presented out of a total of nearly 50 abstracts involving...

2013-09-27 23:28:31

A new type of targeted mesothelioma therapy has yielded promising results in mice, according to a recent published study. Raleigh, NC (PRWEB) September 27, 2013 In a report published on BMC Cancer and detailed on Surviving Mesothelioma, University of Vermont researchers say coating silica microparticles with a special antibody makes it possible to deliver a powerful cancer-fighting drug right at the site of mesothelioma tumors, with better results and fewer side effects than standard...

2013-08-08 16:28:07

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, Aug. 8, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology, today reported financial and operating results as at and for the second quarter ended June 30, 2013. Key Highlights Appointment of New President and CEO -- David Dodd was appointed President...